Research in the Godfrey laboratory focuses on molecular
pathology related to diagnosis and prognosis for cancer. The goal of the
laboratory is to provide clinicians with new, molecular analysis tools
designed to improve the accuracy and timeliness of cancer staging. With
these tools, clinicians and patients will be better informed to make important
treatment decisions, potentially leading to improved survival and/or quality
of life. To achieve these goals, the Godfrey laboratory collaborates closely
with clinicians from the Departments of Surgery and Pathology at both the
University of Rochester Medical Center and the University of Pittsburgh.
Research
in the lab is currently focused primarily in two areas.
1) Detection of occult metastatic disease in lymph nodes
and 2) Integrated genomic and transcriptomic analysis of primary tumors
to predict metastatic spread of tumors and overall patient
outcome. Occult disease detection is performed using
quantitative, real-time RT-PCR and current projects include
lung cancer, esophageal cancer and head and neck cancer. Our integrated
genomics projects utilize Affymetrix arrays for DNA copy number analysis,
gene expression analysis and micro RNA analysis. Projects are currently
focused on lung and esophageal cancer with collaborative miRNA projects
on head and neck cancer and glioblastoma.
In addition we are working with
Biotrove Inc and colleagues at the University of Toledo Ohio to develop
a novel technology for assessment of multi-gene expression signatures in
the clinical environment.
More details of current projects can be found on the main Research
page.
|
|
 |
Tony E. Godfrey, Ph.D.
Associate Professor
of Surgery and Biomedical Genetics
The James P. Wilmot Cancer Center
University
of Rochester Medical Center
New York,
New York
email: tony_godfrey@urmc.rochester.edu
phone:
(585) 273 3112
fax:
(585)
276 2576
 |
|
|
